Teodora Vichova1, Jiri Knot1, Jaroslav Ulman1, Marek Maly2, Zuzana Motovska3. 1. Cardiocentre, Third Faculty of Medicine Charles University and University Hospital Kralovske Vinohrady, Srobarova 50, 10034, Prague, Czech Republic. 2. Department of Biostatistics and Informatics, National Institute of Public Health, Srobarova 48, 10042, Prague, Czech Republic. 3. Cardiocentre, Third Faculty of Medicine Charles University and University Hospital Kralovske Vinohrady, Srobarova 50, 10034, Prague, Czech Republic. motovska.zuzana@gmail.com.
Abstract
BACKGROUND: Patients with diabetes mellitus (DM) or chronic kidney disease (CKD) have a high risk of acute myocardial infarction and recurrent cardiovascular events. According to the previous studies, the combination of the two conditions may have a synergistic impact on prognosis. The aim of this study was to assess the impact of stage of CKD on the outcomes of patients with DM and ST-elevation myocardial infarction (STEMI) treated with percutaneous coronary intervention (PCI). METHODS: Study population consisted of 946 consecutive patients with STEMI who underwent PCI from January 2009 to December 2012 and were followed up until the end of 2013. The all-cause mortality during this period was evaluated in relation to DM and severe or moderate reduction in glomerular filtration rate (GFR categories G4-5, or G3; KDIGO classification). Cox regression analysis adjusted for possible confounding factors was used in statistics. RESULTS: Out of the study population (mean age 63 years, 69.6 % males), 217 (22.9 %) patients had DM. Of them, 10.6 % were in GFR category G4-5 and 32.7 % in G3. The in-hospital mortality rates in patients with DM were 34.8 % for G4-5, 18.3 % for G3, and 4.1 % in G1-2 groups. The all-cause mortality at the end of the follow-up period for diabetics within G4-5 was 2.27 -times higher compared to mortality of diabetics in G1-2 (p = 0.047, Cox regression analysis), and there was a trend toward higher mortality for G3 versus G1-2 (HR 1.64, p = 0.12). CONCLUSION: Severe chronic kidney disease (GFR category 4-5) was significantly associated with all-cause mortality of diabetics with STEMI treated with PCI; the association with severe CKD was stronger compared to moderate CKD.
BACKGROUND:Patients with diabetes mellitus (DM) or chronic kidney disease (CKD) have a high risk of acute myocardial infarction and recurrent cardiovascular events. According to the previous studies, the combination of the two conditions may have a synergistic impact on prognosis. The aim of this study was to assess the impact of stage of CKD on the outcomes of patients with DM and ST-elevation myocardial infarction (STEMI) treated with percutaneous coronary intervention (PCI). METHODS: Study population consisted of 946 consecutive patients with STEMI who underwent PCI from January 2009 to December 2012 and were followed up until the end of 2013. The all-cause mortality during this period was evaluated in relation to DM and severe or moderate reduction in glomerular filtration rate (GFR categories G4-5, or G3; KDIGO classification). Cox regression analysis adjusted for possible confounding factors was used in statistics. RESULTS: Out of the study population (mean age 63 years, 69.6 % males), 217 (22.9 %) patients had DM. Of them, 10.6 % were in GFR category G4-5 and 32.7 % in G3. The in-hospital mortality rates in patients with DM were 34.8 % for G4-5, 18.3 % for G3, and 4.1 % in G1-2 groups. The all-cause mortality at the end of the follow-up period for diabetics within G4-5 was 2.27 -times higher compared to mortality of diabetics in G1-2 (p = 0.047, Cox regression analysis), and there was a trend toward higher mortality for G3 versus G1-2 (HR 1.64, p = 0.12). CONCLUSION: Severe chronic kidney disease (GFR category 4-5) was significantly associated with all-cause mortality of diabetics with STEMI treated with PCI; the association with severe CKD was stronger compared to moderate CKD.
Authors: Ph Gabriel Steg; Stefan K James; Dan Atar; Luigi P Badano; Carina Blömstrom-Lundqvist; Michael A Borger; Carlo Di Mario; Kenneth Dickstein; Gregory Ducrocq; Francisco Fernandez-Aviles; Anthony H Gershlick; Pantaleo Giannuzzi; Sigrun Halvorsen; Kurt Huber; Peter Juni; Adnan Kastrati; Juhani Knuuti; Mattie J Lenzen; Kenneth W Mahaffey; Marco Valgimigli; Arnoud van 't Hof; Petr Widimsky; Doron Zahger Journal: Eur Heart J Date: 2012-08-24 Impact factor: 29.983
Authors: Sjoerd T Nauta; Ron T van Domburg; Rutger-Jan Nuis; Martijn Akkerhuis; Jaap W Deckers Journal: Kidney Int Date: 2013-03-13 Impact factor: 10.612
Authors: Shahyar Michael Gharacholou; Karen P Alexander; Anita Y Chen; Tracy Y Wang; Chiara Melloni; W Brian Gibler; Charles V Pollack; E Magnus Ohman; Eric D Peterson; Matthew T Roe Journal: Am Heart J Date: 2010-05 Impact factor: 4.749
Authors: Karen P Alexander; Anita Y Chen; Matthew T Roe; L Kristin Newby; C Michael Gibson; Nancy M Allen-LaPointe; Charles Pollack; W Brian Gibler; E Magnus Ohman; Eric D Peterson Journal: JAMA Date: 2005-12-28 Impact factor: 56.272
Authors: Nagesh S Anavekar; Scott D Solomon; John J V McMurray; Aldo Maggioni; Jean Lucien Rouleau; Robert Califf; Harvey White; Lars Kober; Eric Velazquez; Marc A Pfeffer Journal: Am J Cardiol Date: 2008-04-01 Impact factor: 2.778
Authors: Parag C Patel; Colby R Ayers; Sabina A Murphy; Ronald Peshock; Amit Khera; James A de Lemos; Jody A Balko; Sachin Gupta; Pradeep P A Mammen; Mark H Drazner; David W Markham Journal: Circ Heart Fail Date: 2009-02-10 Impact factor: 8.790
Authors: Mark D Osten; Joan Ivanov; Jonas Eichhofer; Peter H Seidelin; John R Ross; Alan Barolet; Eric M Horlick; Douglas Ing; Leonard Schwartz; Karen Mackie; Vladimír Dzavík Journal: Am J Cardiol Date: 2008-02-21 Impact factor: 2.778
Authors: Caroline Medi; Gilles Montalescot; Andrzej Budaj; Keith A A Fox; José López-Sendón; Gordon FitzGerald; David B Brieger Journal: JACC Cardiovasc Interv Date: 2009-01 Impact factor: 11.195
Authors: Karthik Balasubramaniam; Girish N Viswanathan; Sally M Marshall; Azfar G Zaman Journal: Cardiol Res Pract Date: 2012-01-05 Impact factor: 1.866